Shares of Gilead Sciences were down more than 5.5% in midday trading.
Shares of pharma giant Gilead Sciences fell sharply today after details of a clinical trial for a much-anticipated antiviral drug suggested no immediate benefit for patients diagnosed with COVID-19.
Read the full article here.
This content was originally published by Fast Company. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fast Company